End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.98 CNY | +1.13% | -5.91% | -30.18% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company sustains low margins.
- With an expected P/E ratio at 117.62 and 98.8 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.18% | 19Cr | - | ||
-1.52% | 836.95Cr | B- | ||
+10.68% | 583.76Cr | B | ||
+26.94% | 539.81Cr | C | ||
-5.09% | 436.65Cr | C | ||
-52.54% | 322.85Cr | D+ | ||
+14.18% | 279.52Cr | - | - | |
+32.50% | 225.64Cr | C | ||
-6.47% | 221.61Cr | B- | ||
-1.69% | 187.43Cr | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 688217 Stock
- Ratings Shanghai Rightongene Biotechnology Co., Ltd.